Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck And Cape Town Target Malaria Drug

by Alex Scott
November 30, 2015 | A version of this story appeared in Volume 93, Issue 47

Merck KGaA and the University of Cape Town will jointly run a research program developing a potential treatment for malaria. The collaboration is set to extend to other tropical diseases. It will use H3D, the university’s drug discovery and development center, and Merck’s compound library to develop antimalarial drug candidates. Members of Merck’s executive board visited 10 African countries in the past week to underscore the firm’s commitment to the continent, Merck says.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.